Details of Metabolite
| Full List of Protein(s) Regulating This Metabolite | ||||||
|---|---|---|---|---|---|---|
| Apolipoprotein (Apo) | ||||||
| Apolipoprotein A-II (APOA2) | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
| Detailed Information |
Protein Info
click to show the details of this protein
|
|||||
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[1] | ||||
| Introduced Variation | Mutation (-265T >C(rs5082)) of APOA2 | |||||
| Induced Change | Uridine concentration: increase (FC = 1.13) | |||||
| Summary | Introduced Variation
|
|||||
| Disease Status | Obesity [ICD-11: 5B81] | |||||
| Details | It is reported that mutation (-265T >C(rs5082)) of APOA2 leads to the increase of uridine levels compared with control group. | |||||
| Equilibrative nucleoside transporter (ENT) | ||||||
| Equilibrative nucleoside transporter 2 (SLC29A2) | Click to Show/Hide the Full List of Regulating Pair(s): 2 Pair(s) | |||||
| Detailed Information |
Protein Info
click to show the details of this protein
|
|||||
| Regulating Pair (1) |
Experim Info
click to show the details of experiment for validating this pair
|
[2] | ||||
| Introduced Variation | Inhibition (Nitrobenzylthioinosine (NBMPR)) of SLC29A2 | |||||
| Induced Change | Uridine concentration: decrease (FC = 0.15) | |||||
| Summary | Introduced Variation
|
|||||
| Disease Status | Healthy individual | |||||
| Details | It is reported that inhibition of SLC29A2 leads to the decrease of uridine levels compared with control group. | |||||
| Regulating Pair (2) |
Experim Info
click to show the details of experiment for validating this pair
|
[2] | ||||
| Introduced Variation | Overexpression of SLC29A2 | |||||
| Induced Change | Uridine concentration: increase | |||||
| Summary | Introduced Variation
|
|||||
| Disease Status | Healthy individual | |||||
| Details | It is reported that overexpression of SLC29A2 leads to the increase of uridine levels compared with control group. | |||||
| GPCR secretin (GPCR-2) | ||||||
| Glucagon receptor (GCGR) | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
| Detailed Information |
Protein Info
click to show the details of this protein
|
|||||
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[3] | ||||
| Introduced Variation | Knockout of Gcgr | |||||
| Induced Change | Uridine concentration: increase (FC = 1.7) | |||||
| Summary | Introduced Variation
|
|||||
| Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
| Details | It is reported that knockout of GCGR leads to the increase of uridine levels compared with control group. | |||||
| Hydrolases (EC 3) | ||||||
| Sulfatase sulf-1 (SULF1) | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
| Detailed Information |
Protein Info
click to show the details of this protein
|
|||||
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[4] | ||||
| Introduced Variation | Knockdown (shRNA) of SULF1 | |||||
| Induced Change | Uridine concentration: decrease (FC = 0.68 / 0.82) | |||||
| Summary | Introduced Variation
|
|||||
| Disease Status | Ovarian cancer [ICD-11: 2C73] | |||||
| Details | It is reported that knockdown of SULF1 leads to the decrease of uridine levels compared with control group. | |||||
| Lyases (EC 4) | ||||||
| Cystathionine gamma-lyase (CTH) | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
| Detailed Information |
Protein Info
click to show the details of this protein
|
|||||
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[5] | ||||
| Introduced Variation | Knockout of Cth | |||||
| Induced Change | Uridine concentration: increase (FC = 2.61) | |||||
| Summary | Introduced Variation
|
|||||
| Disease Status | Organic acid disorderss [ICD-11: 5C50] | |||||
| Details | It is reported that knockout of Cth leads to the increase of uridine levels compared with control group. | |||||
| Nitrogen permease regulator (NPR) | ||||||
| Natriuretic peptide receptor B (NPR2) | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
| Detailed Information |
Protein Info
click to show the details of this protein
|
|||||
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[6] | ||||
| Introduced Variation | Deletion of NPR2 | |||||
| Induced Change | Uridine concentration: increase | |||||
| Summary | Introduced Variation
|
|||||
| Disease Status | Healthy individual | |||||
| Details | It is reported that deletion of NPR2 leads to the increase of uridine levels compared with control group. | |||||
| Pore-forming PNC peptide (PNC) | ||||||
| Cellular tumor antigen p53 (TP53) | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
| Detailed Information |
Protein Info
click to show the details of this protein
|
|||||
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[7] | ||||
| Introduced Variation | Knockout of TP53 | |||||
| Induced Change | Uridine concentration: increase (Log2 FC=1.28) | |||||
| Summary | Introduced Variation
|
|||||
| Disease Status | Colon cancer [ICD-11: 2B90] | |||||
| Details | It is reported that knockout of TP53 leads to the increase of uridine levels compared with control group. | |||||
| Transferases (EC 2) | ||||||
| Pyridoxal kinase (PDXK) | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
| Detailed Information |
Protein Info
click to show the details of this protein
|
|||||
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[8] | ||||
| Introduced Variation | Knockout (CRISPR/Cas9 sgRNA) of PDXK | |||||
| Induced Change | Uridine concentration: decrease | |||||
| Summary | Introduced Variation
|
|||||
| Disease Status | Acute myeloid leukaemia [ICD-11: 2A60] | |||||
| Details | It is reported that knockout of PDXK leads to the decrease of uridine levels compared with control group. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.


